Aristotle University Of Thessaloniki (AUTH)
Το κάπνισμα σε σχιζοφρενείς υπό φαρμακευτική αγωγή: πρόγραμμα περιορισμού - διακοπής του καπνίσματος σε μια ψυχιατρική κλινική
Abstract
dc:descriptionIn the present study we assessed the impact of smoking on the metabolism of psychotropic drugs, as well as, possible correlations of smoking with psychopathology and extrapyramidal symptoms. We also conducted a smoking reduction/cessation program in a group of chronic schizophrenic inpatients. In the first study, participants were 40 schizophrenic patients hospitalized in the acute ward of the 1st Psychiatric Department of Aristotle University of Thessaloniki. Demographic data (sex, age, educational level, and family status), data regarding the history of illness (duration and family history for psychiatric disorder), alcohol/substance abuse, and the history of smoking (duration, number of cigarettes/day, cigarette nicotine and tar proof, and level of nicotine dependence with the Fagerström Test for Nicotine Dependence), as well as drug treatment, were recorded for every patient. Moreover, psychopathology (Positive and Negative Syndrome Scale, PANSS), depression (Calgary Depression Scale for Schizophrenia, CDSS) and extrapyramidal symptoms (Extrapyramidal Rating Scale, ERS) were assessed. Finally, the impact of smoking on the metabolism of psychotropic drugs was studied by measuring CYP1A2 activity. This activity was determined by using the molar ratio (MR) of caffeine and its metabolites in urine and saliva. The second study was aimed at the application of a smoking reduction/cessation program. This program included 16 smokers (14 of them with schizophrenia) who were chronic inpatients, hospitalized in the longterm ward of the Department. As the patients' motivation to quit or at least decrease their smoking (Intention to Quit Smoking) was poor, we emphasized the acceptance and establishment of a smoking room for those patients who wished to smoke. So we applied a simple behavioral program with a token economy, hoping also to achieve the reduction, if not the cessation of smoking. Thirty of the 40 patients included in the first study were smokers (75%), 83% of the men and 54.5% of the women. Eighty percent of the smokers reported consuming 20-80 cigarettes per day (83% men and 67.5% women). Significantly more male patients than female patients were smokers; also, smokers, were more likely than non-smoking patients to have first-degree relative who was a smoker. Smokers presented marginally increased substance abuse relative to non-smokers. They also had marginally higher scores on the negative subscale of PANSS and on the CDSS compared with no smokers. MR of caffeine metabolites in urine and saliva were significantly higher among schizophrenic patients who smoked rather than in non-smokers, even after we included gender in the comparison as covariate. The smoking restriction was at first related to location and compliance with the rule to smoke only in the smoking room. Men's compliance gradually but steadily increased, despite the initial "violations". Compliance was rewarded through the application of a behavioral (token economy) and through discussions within the psychotherapeutic team. Women continued to smoke in the living room; they avoided smoking in the wards and in the corridors, but they refused to stay in the spacious smoking room where men were predominant. We accepted this «violation», as their small number did not cause a great deviation from our aim to clear out smoking in the main areas of the long-term ward. In contrast to the successful intervention in restricting the location of smoking, restricting the amount of smoking was less successful. Negative and depressive symptoms of schizophrenia appeared to be related with increase smoking rate in patients suffering from this illness, as if tobacco use is a form of self-medication. Moreover, given the induction of CYP1A2 and the subsequent increase of metabolism of most antipsychotic drugs, smoking should be co-evaluated when the patient is not improving despite receiving adequate doses of medication. Regarding smoking cessation efforts, for patients who have great difficulties in reducing cigarette consumption, such as chronic inpatients, a clear designation of smoking areas and a program that would not only prohibit but also providealternatives (such as the establishment of special smoking areas) are needed.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2002
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Μποζίκας, Βασίλειος-Παντελεήμων
- Bozikas, Vasileios-Panteleimon
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/13378